About Aurigene Pharmaceutical
Aurigene Pharmaceutical is a Healthcare company based in Bengaluru (India) founded in 2020. It provides integrated CRO and CDMO services for drug discovery and manufacturing. It operates on a B2B and Service-based model. The company has 906 employees. Its website aurigeneservices.com draws about 16 thousand monthly visits. Its Indian entity Aurigene Pharmaceutical Services Limited reported revenue of ₹645 Cr. Aurigene Pharmaceutical offers products and services including Small Molecule Discovery, Small Molecule CDMO, Biologics Services, and Formulation Services. Its focus areas include Pharmaceuticals, Drug Discovery, Small Molecule and Biotechnology. Its competitors include Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma and 5 more; 4 of its 10 listed competitors have raised funding.
Company details
Aurigene Pharmaceutical Services is a global CRDMO specializing in end-to-end solutions for small and large molecules, including drug discovery, development, and manufacturing. It operates through flexible models like FTE and FFS, serving global pharma and biotech clients. Based in India, with facilities in Hyderabad, Bangalore, the UK, and Mexico, it focuses on compliance, sustainability, and innovation in areas like chemistry, biology, and biologics.
- Headquarters Bengaluru, India
- Employees 906
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website aurigeneservices.com
- Social LinkedIn X YouTube
- Legal Name Aurigene Pharmaceutical Services Limited
- Date of Incorporation 16 Sep, 2019
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹645 Cr
FY 2025 · +44% YoY
- Net Profit₹64.94 Cr
FY 2025 · 10% margin
- EBITDA₹184 Cr
FY 2025 · 29% margin
- Employee Count906
Associated legal entities of Aurigene Pharmaceutical
Aurigene Pharmaceutical operates through Aurigene Pharmaceutical Services Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Aurigene Pharmaceutical Services Limited CIN U74999KA2019PLC127964 | Active | 16 Sep 2019 | Bangalore, Karnataka | ₹645 Cr | 906 | 7 | View details |
Products & Services of Aurigene Pharmaceutical
Aurigene Pharmaceutical offers a comprehensive portfolio of products and services, including Small Molecule Discovery, Small Molecule CDMO, Biologics Services, and Formulation Services.
Services for chemistry and biology in drug development processes.
Development and production of pharmaceutical intermediates and APIs.
From antibody discovery to clinical manufacturing of biologics.
Development of various dosage forms for pharmaceutical products.
Apps and channels of Aurigene Pharmaceutical
its YouTube channel Aurigene Pharmaceutical Services has 685 subscribers and 30 videos.
Videos from Aurigene Pharmaceutical
The most watched videos on Aurigene Pharmaceutical's YouTube channel, Aurigene Pharmaceutical Services (685 subscribers). Click a video to play it here.
More on Aurigene Pharmaceutical Services.
Board of directors of Aurigene Pharmaceutical Services Limited (Aurigene Pharmaceutical)
Aurigene Pharmaceutical Services Limited is the primary company behind Aurigene Pharmaceutical. The board of Aurigene Pharmaceutical Services Limited currently have 6 directors; the longest-serving is Erez Israeli, appointed in 2019. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Erez Israeli DIN 08563726 | Director | 16 Sep 2019 | 7 yrs 1 mo | Aurigene Pharmaceutical Services Limited |
| Deepak Sapra DIN 08563727 | Director | 16 Sep 2019 | 7 yrs 1 mo | Aurigene Pharmaceutical Services Limited |
| Mannam Venkata Narasimham DIN 02677423 | Director | 16 Sep 2019 | 7 yrs 1 mo | Aurigene Pharmaceutical Services Limited |
| Atul Sachdeva DIN 07645130 | CFO | 27 Jul 2022 | 4 yrs 2 mo | Aurigene Pharmaceutical Services Limited |
| Jesal Agarwal DIN 06986253 | Director | 29 Mar 2024 | 2 yrs 6 mo | Aurigene Pharmaceutical Services Limited |
| Sapna DIN 08434059 | Company Secretary | 14 Nov 2024 | 1 yr 11 mo | Aurigene Pharmaceutical Services Limited |
Financials of Aurigene Pharmaceutical
Figures of Aurigene Pharmaceutical Services Limited, the primary company behind Aurigene Pharmaceutical, for FY 2025. Revenue was ₹645 Cr (+44% year on year). Net profit was ₹64.94 Cr (10% margin). EBITDA was ₹184 Cr (29% margin). Revenue has grown at a compounded annual rate of +21% over three years.
- ₹645 CrRevenue · FY 2025 · +44% YoY
- ₹64.94 CrNet profit · 10% margin
- ₹184 CrEBITDA · 29% margin
- ₹156 CrPaid-up capital
- 906Employees (provident fund records)
- +21%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Aurigene Pharmaceutical Services Limited are on its company page.
Detailed financial statements for Aurigene Pharmaceutical
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Aurigene Pharmaceutical
Aurigene Pharmaceutical has 10 listed competitors in our database, 4 of them funded. They include Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| almacgroup.com | 2001 | Craigavon, United Kingdom | $338.8M | 2,109 | Integrated CDMO services for biopharma R&D and manufacturing are offered. | |
| indoco.com | 1947 | Mumbai, India | – | 6,291 | APIs manufacturing and formulation services are provided in therapeutic segments. | |
| concordbiotech.com | 2000 | Ahmedabad, India | – | 1,598 | APIs and enzymes are manufactured through fermentation by the CDMO. | |
| bdrpharma.com | 2003 | Mumbai, India | $88.16M | 1,864 | APIs and finished products are developed and manufactured. | |
| aurobindo.com | 1986 | Hyderabad, India | – | 1,010 | Generic biocatalytic solutions are provided for pharmaceutical applications. | |
| asymchem.com | 1995 | Morrisville, United States | – | 48 | APIs and peptides are developed and manufactured by Asymchem. | |
| seqens.com | 2003 | Ecully, France | – | 44 | Contract manufacturing services for small molecules and peptides are provided. | |
| continuuspharma.com | 2012 | Woburn, United States | $7.73M | 47 | MIT-Novartis spinoff offering continuous manufacturing solutions to remove the proverbial wall between API and FDF manufacturing in small molecule development | |
| pharm-int.com | 1994 | Hunt Valley, United States | – | 248 | Pharmaceutical dosage forms are manufactured by this CDMO. | |
| aptuit.com | 2004 | Greenwich, United States | $14.23M | – | Contract research and development services for small molecules are offered. |
Detailed competitors of Aurigene Pharmaceutical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aurigene Pharmaceutical
The website of Aurigene Pharmaceutical (aurigeneservices.com) receives about 16.1K visits a month and ranks #1,244,986 among all websites worldwide, #1,574 in Biotechnology and Pharmaceuticals.
- Monthly visits16.1K
▼ 14.8% vs previous month
- Unique visitors9.6K
per month
- Global rank#1,244,986
among all websites
- Category rank#1,574
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit2.4
- Average visit5 min 07 sec
- DevicesDesktop 18% · Mobile 82%
Websites whose visitors overlap most with Aurigene Pharmaceutical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| aurigene.com | 100% | 5.5K | #3,284,144 | View details | |
ipa-india.org | ipa-india.org | 96% | – | #2,901,611 | – |
| syngeneintl.com | 90% | 94K | #525,515 | View details | |
| patheon.com | 84% | 89.1K | #488,648 | View details | |
| sravathi.ai | 32% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Aurigene Pharmaceutical
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as Aurigene Pharmaceutical (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aurigene Pharmaceutical
Complete news archive for Aurigene Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aurigene Pharmaceutical
Aurigene Pharmaceutical was founded in 2020.
Aurigene Pharmaceutical is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Aurigene Pharmaceutical has 906 employees.
The primary company behind Aurigene Pharmaceutical, Aurigene Pharmaceutical Services Limited, reported revenue of ₹645 Cr for FY 2025, up 44% year on year.
Aurigene Pharmaceutical Services is a global CRDMO specializing in end-to-end solutions for small and large molecules, including drug discovery, development, and manufacturing. It operates through flexible models like FTE and FFS, serving global pharma and biotech clients. Based in India, with facilities in Hyderabad, Bangalore, the UK, and Mexico, it focuses on compliance, sustainability, and innovation in areas like chemistry, biology, and biologics.
Aurigene Pharmaceutical's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Almac Group.
Aurigene Pharmaceutical offers Small Molecule Discovery, Small Molecule CDMO, Biologics Services, and Formulation Services.
Aurigene Pharmaceutical operates through Aurigene Pharmaceutical Services Limited.
The legal entities of Aurigene Pharmaceutical currently have 7 directors, including Erez Israeli, Deepak Sapra, Mannam Venkata Narasimham and others.